



Do you see patients with severe cutaneous drug reactions (SCAR)?

Are you interested in joining a network to harmonise care, research mechanisms, biomarkers for prevention & treatment strategies?

We need you! Attend our one day symposium to introduce & ignite the network.



Thursday | 12th September | 9am - 4pm

Introduction: why a AFRiSCAR registry – Ranks Lehloenyia & Jonny Peter

AFRiSCAR progress update – Ranks Lehloenyia & Jonny Peter

Pharmacogenomics SJS/TEN: Nevirapine – Elizabeth Phillips

The REDCAP database: step-by-step – Rhodine Smith

GROOTE SCHUUR HOSPITAL MULTI-DISCIPLINARY DRUG ALLERGY CLINIC

In September 2015, Associated Professors Lehloenyia (Dermatology), Peter (Allergy and Clinical Immunology) and Dlamini (Infectious Diseases) established a multidisciplinary drug allergy clinic at Groote Schuur Hospital – the first such clinic on the continent. The clinic is focused on the management of immune-mediated adverse drug reactions (IM-ADRs); particular IM-ADRs occurring in the context of HIV co-infection. The spectrum of all IM-ADRs is included, attempting to move beyond individual clinic disciplines to consider the spectrum of phenotypes caused by individual drugs, deepening mechanistic understanding and improving holistic patient care.

Guest International Faculty – Prof Elizabeth Phillips



Elizabeth Phillips, MD is Professor of Medicine, Pharmacology, Pathology, Microbiology and Immunology and is Director of Personalized Immunology at the Oates Institute for Experimental Therapeutics at Vanderbilt University Medical Center. She is also Director of the Centre for Clinical Pharmacology and Infectious Diseases at the Institute for Immunology and Infectious Diseases, Murdoch University in Perth Western Australia. She is also co-director for the personalized-care scientific working group for the Vanderbilt Center for AIDS Research. She has been immensely successful in answering important scientific questions about variation in drug responses, in particular interactions between drugs and the immune system. She played a key leadership role in establishing HLA-B*57:01 and the roadmap from discovery to translation of HLA-B*57:01 as a routine screening marker used prior to abacavir prescription to prevent hypersensitivity. Her current work focuses on defining the immunopathogenesis of severe adverse drug reactions and in particular using innovative technologies to define genetic, molecular and cellular signatures in severe cutaneous adverse drug reactions such as SJS/TEN that will guide prevention, early diagnosis and define new therapeutic targets. She is currently part of the PGRN and a principal investigator on a P50 grant to study the immunopathogenesis and improvement in the prediction of HLA-mediated drug reactions.



National Research Foundation